UNSPSC 51263161: Cloranolol hydrochloride

This classification denotes a beta-adrenergic blocking agent with the molecular formula C13H19Cl2NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 79SQ2WFQ23, chemically known as (+/-)-dichlorophenoxy)-3-tert-butylamino-2-propanol hydrochloride, but more generally known as cloranolol hydrochloride, which bears US NIH Compound Identifier 162743. European Medicines Agency schedules cloranolol hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06752MIG.

Most nations, for tariff purposes, schedule cloranolol hydrochloride under HS 29221980. SMILES: CC(C)(C)NCC(COC1CC(CCC1CL)CL)O.CL.

UNSPSC 51263161 Cloranolol hydrochloride is a Commodity code that nominally describes a specific pharmaceutical compound, but the recent state and local opportunities tagged under it show a significant mismatch: the only directly relevant solicitation is Seminole County, Florida's IFB for naloxone and drug deactivation systems, which is a public-health intervention product, not cloranolol hydrochloride. The second opportunity—Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs—is exploratory market intelligence gathering for pharmacy benefit redesign and does not specify cloranolol or any particular pharmaceutical. The code itself does not appear to be driving coherent procurement activity in state and local markets; when opportunities are tagged to it, they tend to address broader pharmaceutical acquisition, harm-reduction supplies, or pharmacy-program restructuring rather than the specific active pharmaceutical ingredient the code nominally names.

Seminole County's naloxone and drug deactivation systems procurement (IFB 60459723LAS, response due July 26, 2023) is the only concrete recent solicitation under this code, requesting 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The Texas RFI (HHS0017013, posted April 3, 2026) is an information-gathering exercise by a state health agency rather than a competitive bid for a specific product. The geographic spread is limited to Florida and Texas in recent activity, with no indication of sustained multi-jurisdiction interest in cloranolol hydrochloride procurement specifically. Business developers should note that this code's nominal scope and actual state and local purchasing patterns are divergent; opportunities may be more effectively tracked through broader pharmaceutical acquisition or harm-reduction supply codes rather than this commodity-level designation.